Cognite Awarded Google Cloud Technology Partner of the Year 2019 for Manufacturing
Cognite, a global industrial DataOps and AI software-as-a-service (SaaS) company, was announced as the 2019 Google Cloud Technology Partner of the Year for Manufacturing. Cognite currently supports the full-scale digital transformation of heavy-asset industries around the world, empowering industrial companies to save on costs, reduce environmental footprints to improve sustainability and increase profits made possible through Cognite Data Fusion (CDF).
This international award recognizes one Partner that has implemented multiple Google Cloud technologies to demonstrate how they work together easily to deliver solutions based on individual customer needs.
“We appreciate being recognized for creating value through our software products by turning historical and real-time industrial data into insights. We have seen a number of our manufacturing clients develop and deliver new digital services and even transform their business model as a result of using Cognite Data Fusion,” said Dr. John Markus Lervik, Co-Founder and CEO of Cognite. “It is important for us to make a true impact on our customers while shaping the digital future of the world’s largest, most vital industries.”
“With Cognite making live and contextualized data available, we at Framo, an Alfa Laval company, are able to create our own software applications to predict the status of our equipment, allowing us to plan efficient maintenance. The new system sends intelligent data on our pumps, so we can predict how the pumps will perform in the future. This has enabled us to sign a groundbreaking long term smart contract with our customer Aker BP,” explains Trond Petter Abrahamsen, Managing Director of Framo Services AS.
“We’re proud to recognize Cognite as our Technology Partner of the Year for Manufacturing,” said Kevin Ichhpurani, Corporate Vice President, Global Ecosystem at Google Cloud. “Cognite’s data capabilities, running on Google Cloud, can help manufacturers leverage data to optimize processes and operate more efficiently. We look forward to a continued partnership with Cognite to help manufacturing businesses digitally transform with Google Cloud.”
Cognite Data Fusion is an industrially specialized DataOps and AI platform to optimize manufacturing facilities intelligently by reducing downtime, improving equipment effectiveness, and optimizing forecasting. Through integrated hybrid AI analytics tools, advanced visualization in real-time dashboards, and low-code application development services, Cognite Data Fusion enables heavy asset customers to operationalize and scale their digital programs to unlock ROI at scale.
Cognite has consistently produced proven results for the heavy asset industry, which accounts for around 20-30% of the gross domestic product worldwide, with main verticals in energy and oil & gas, power & utilities, and manufacturing. Operating costs have been reduced by 15-18% through digitalization of the industrial assets and work processes. Cognite Data Fusion utilizes Google Cloud services like Cloud Bigtable, Kubernetes Engine, Stackdriver, Pub/Sub, Cloud spanner, Cloud Storage, Cloud SQL, Auto ML, and ML Engine.
About Cognite
Cognite is a global industrial AI Software-as-a-Service (SaaS) company supporting the full-scale digital transformation of heavy-asset industries around the world. Their key product, Cognite Data Fusion (CDF), empowers companies with contextualized OT/IT data to drive industrial applications that increase safety, sustainability, and efficiency, and drive revenue. www.cognite.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200406005628/en/
Contact information
Michelle Holford
Cognite
Global Head of PR
+1 512-744-3420
michelle.holford@cognite.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aptiv and Vecna Robotics to Develop Next Generation Autonomous Mobile Robots18.12.2025 14:00:00 CET | Press Release
Aptiv PLC (NYSE: APTV), a global industrial technology leader, and Vecna Robotics, a pioneer in AI-driven autonomous material handling solutions, today announced a strategic collaboration to co-develop next-generation Autonomous Mobile Robot (AMR) solutions designed to deliver cost-efficient automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218958100/en/ Aptiv’s advanced perception portfolio and machine learning technologies will be integrated into Vecna Robotics’ platform. This partnership combines Aptiv’s industry-leading portfolio, with Vecna Robotics’ advanced autonomy and orchestration platform to provide safer, more efficient, and scalable material handling systems. “Automation is transforming the way goods move through warehouses and factories, with devices that sense, think and act in real time,” said Javed Khan, Executive Vice President, Intelligent Systems, Aptiv. “Our collaboration with Vecna Robotics
Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions18.12.2025 14:00:00 CET | Press Release
Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health, today announced its launch with a $165 million financing. The Series A, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet will support the advancement of Syremis’ pipeline through clinical proof of concept. Schizophrenia and other psychotic disorders remain among the most debilitating and underserved conditions worldwide, with more than 20 million people affected and facing considerable disability, elevated relapse rates, and reduced life expectancy. Despite decades of need, current treatments often fall short in both efficacy and tolerability. Syremis’ lead program, ST-905, is a dual M1/M4 muscarinic agonist under development for schizophrenia and other neuropsychiatric conditions and is currently in Phase 1. The molecule’s differentiated potency
Cinemo at CES 2026: Hyper-Personalized Experiences in the Car and Beyond18.12.2025 13:55:00 CET | Press Release
Cinemo, a global leader and highly innovative one-stop-shop provider for fully integrated digital media products is presenting its newest innovations in exclusive live demos at CES 2026 in Las Vegas, from January 6-9. Cinemo will present a range of in-car experiences that bring intelligence, hyper-personalization, and entertainment to every moment - elevating every ride into a unique experience for drivers and passengers. From collaborative trip planning to effortless onboarding, every feature is crafted to enable fascinating experiences with the right content at the right time for the right audience - for the perfect ride. Passengers can enjoy personalized media recommendations, immersive gaming, and a consistent, intuitive experience across every seat, screen, and journey. This will mark Cinemo’s first time presenting these demo showcases live of breakthrough solutions that redefine the future of in-vehicle intelligence. Cinemo is bringing agentic AI into the vehicle and is extending
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press Release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom